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Abstract
Background—In 2009, the United States Preventive Services Task Force (USPSTF) 
recommended against routine mammography screening for women aged 40–49 years. This revised 
recommendation was widely criticized and has sparked off intense debate. The objectives of this 
study are to examine the impact of the revised recommendation on the proportion of women 
receiving mammograms and how the effect varied by age.
Methods—We identified women who had continuous health insurance coverage and who did not 
have breast cancer between 2008 and 2011 in the Truven Health MarketScan Commercial Claims 
Databases using mammogram procedure codes. Using women aged 50–59 years as a control 
group, we used a differences-in-differences approach to estimate the impact of the revised 
recommendation on the proportion of women ages 40–49 years who received at least one 
mammogram. We also compared the age-specific changes in the proportion of women ages 35–59 
years who were screened before and after the release of the revised recommendation.
Results—The proportion of women screened among the 40–49 and 50–59 age groups were 58.5 
and 62.5%, respectively, between 2008 and 2009, and 56.9 and 62.0%, respectively, between 2010 
and 2011. After 2009, the proportion of women screened declined by 1.2 percentage point among 
women aged 40–49 years (P < 0.01). The proportion of women screened decreased for all ages, 
and decreases were larger among women closer to the 40-year threshold.
Conclusions—The 2009 USPSTF breast cancer recommendation was followed by a small 
reduction in the proportion of insured women aged 40–49 years who were screened. Reductions 
were larger among women at the younger end of the age range, who presumably had less prior 
experience with mammography than women nearing 50.
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Introduction
In November 2009, the United States Preventive Services Task Force (USPSTF) released a 
new breast cancer recommendation that does not recommend routine breast cancer screening 
for average-risk women aged 40–49 years. The USPSTF recommended that decisions about 
screening in this age group be individualized: “the decision to start regular, biennial 
screening mammography before age 50 years should be an individual one and should take 
into account patient context, including the patient’s values regarding specific benefits and 
harms [1].” The previous version of the recommendation, issued in 2002, endorsed annual or 
biennial mammography screening for women aged 40 and older [2]. In January 2016, the 
USPSTF reaffirmed the 2009 revised recommendation by emphasizing the potential harms 
of screening and lower benefit of screening among women in their 40 s [3, 4]. The 2016 
recommendation for women aged 40–49 stated that “women who place a higher value on the 
potential benefit than the potential harms may choose to begin biennial screening between 
the ages of 40 and 49 years [5].”
The 2009 recommendation was widely covered in the media [6] and subject to fierce 
criticism from patient advocates [7], clinicians, and policy makers after the release. Some 
radiologists appealed to the USPSTF to rescind the revised recommendation [8, 9]. After the 
release, the American Cancer Society, the American College of Radiology, and the Society 
of Breast Imaging continued to recommend annual screening for women aged 40 and older 
and strongly criticized the USPSTF recommendation [10–13]. In 2015, the American Cancer 
Society updated their recommendation and advised women to start annual mammography 
screening at age 45 and transition to biennial screening at age 55 [14].
In this study, we evaluate the impact of the revised USPSTF recommendation on the 
proportion of women receiving mammograms using data from a large private insurance 
claims database. The change in the recommendation is of inherent interest, given the 
prevalence and cost of breast cancer, and provides an opportunity to study how physicians 
and patients respond to changes in guidelines. In a national telephone survey conducted one 
year after the revised USPSTF recommendation was issued, 51% of women aged 40–49 
years were aware of the new recommendations [15]. However, only 34% had a favorable 
opinion of the changes. We compare changes in the proportion of women who received a 
mammogram between women ages 40 and 49 years and 50 and 59 years and evaluate 
changes in age-specific rates among women ages 35–59 years.
Previous studies have examined trends in the proportion of women ages 40–49 years 
screened before and after the release of the 2009 revision to the USPSTF’s breast cancer 
recommendation [16–21]. These studies have mostly found that changes in the proportion of 
women screened between 2008 and 2010 or 2011 were small and nonsignificant. For 
example, using Behavioral Risk Factor Surveillance System data, Block et al. [16] found 
that the proportion of women ages 40–49 years who were screened decreased from 53.2% in 
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2008 to 51.7% in 2010 (−2 percentage points). However, the proportion of women ages 50–
74 years who were screened declined by a slightly larger amount, from 65.2 to 62.4% (−2.8 
percentage points). Howard and Adams [18] used Medical Expenditure Panel Survey data 
and found that declines in the proportion of women screened were less than 1 percentage 
point in both groups. Using National Health Interview Survey data, Pace et al. [17] found 
that the proportion of women ages 40–49 years who were screened actually increased 
between 2008 and 2011, from 46.1 to 47.5% (1.4 percentage points). The proportion of 
women ages 50–74 years who were screened also increased from 57.2 to 59.1% (1.9 
percentage points). Using private insurance claims, Wang et al. [20] found that there was a 
small difference in predicted versus observed screening rates among women ages 40–49 
years in 2011, and Wharam et al. [19] found that the proportion of women ages 40–49 years 
who received a mammogram in 2012 was 4.3 percentage points below the predicted 
proportion, which takes pre-existing trends into account.
The ability of previous studies to draw conclusions about the impact of the 2009 revision to 
the screening recommendations has been limited by small sample sizes, which are sufficient 
for measuring mammography trends in broad age groups but not at a more granular level. In 
2009, women ages 40–49 years would have varied in terms of their prior exposure to 
mammography. Women ages 49 years who were screened annually before 2009 would have 
had nine prior mammograms. Conversely, some 40-year-old women would not have had a 
mammogram. Faced with a change in screening recommendations in 2009, women in the 
40–49 years age group may have interpreted the recommendation in light of their prior 
exposure to mammography. The size of our sample permits us to examine changes in 
screening by individual age group (for example, 39 vs. 40 years and 40 vs. 41 years) instead 
of across broad age groups. We hypothesize that the revision had a larger impact on 
screening among women closer to the 40-year-old age threshold compared to women close 
to the age of 50 years, many of whom were previously screened.
Methods
Data and sample
We measured the proportion of women screened by age and period using the Truven Health 
MarketScan Commercial Claims and Encounters Database over the period 2008–2011 [22]. 
The commercial database includes records for about 40 million insured persons ages 0–64 
years, nearly one quarter of the privately insured population. The geographic distribution by 
US Census regions of insured persons is as follows: south, 40%; north central, 23%; west, 
20%; and northeast 17%. The regional distribution of patients in the Truven claims can shift 
over time depending on the composition of employers using Truven to process their claims 
data.
Our sample includes women who were continuously enrolled with their insurer for at least 
24 months in either the pre-recommendation period (2008–2009) or the post-
recommendation period (2010–2011). We excluded women with one or more claims listing a 
diagnosis code for breast cancer. We measured changes in mammography rates among 
women ages 40–49 years, the age group of interest, and women ages 50–59 years, a 
concurrent control group. We measured changes in age-specific mammography rates among 
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women aged 35–59 years. In our preliminary analyses, we found that there was a sharp 
increase in mammography rates among women who were around age 40, and so we selected 
age 35 as the starting point of the age range to help better understand the trends around age 
40.
Variable coding
We identified mammograms using Healthcare Common Procedure Coding System (HCPCS) 
codes for screening mammograms (76083, 76085, 76092, 77052, 77057, G0202, and 
G0203) on outpatient and physician office claims [23]. In a sensitivity analysis, we 
identified mammograms using codes for screening mammograms as well as codes for 
diagnostic mammograms (76090, 76091, 77051, 77055, 77056, G0204, G0205, G0206, 
G0207, 76082). Some physicians may bill for screening mammograms using diagnostic 
codes [24, 25].
We measured the receipt of mammography biennially beginning 1 January 2008. We 
counted a woman as having received a mammogram if she had at least one claim listing one 
of the aforementioned HCPCS codes during a two-year interval.
Age was measured using 2008 and 2010 enrollment records for women in the pre-period and 
women in post-period (after the 2009 recommendation), respectively. We also used 
enrollment records to measure whether the patient was the primary policyholder or spouse of 
the primary policyholder, the type of plan (health maintenance organization [HMO]/
preferred provider organization [PPO]/consumer-directed health plan [CDHP], point-of-
service plan [POS], or other), and patients’ region of residence (northeast, north central, 
south, or west). We used inpatient, outpatient, and physician office claims to measure 
Elixhauser comorbidities [26, 27].
Statistical analysis
Difference-in-difference analysis—Previous studies have used a difference-in-
difference approach to estimate the impact of the 2009 revision to the USPSTF breast cancer 
screening recommendation on the proportion of women screened. We applied a difference-
in-difference estimator to our data to facilitate comparison between our results with those 
from prior studies. The unadjusted difference-in-difference estimator is the change in the 
proportion of women screened among women ages 50–59 years subtracted from the change 
among women ages 40–49 years. Difference-in-difference estimators control for underlying 
trends in the proportion of women screened that are common to both age groups and are 
robust to differences in unobserved, time-invariant enrollee characteristics between groups.
We also constructed a regression-based difference-in-difference estimator that adjusts for 
observed patient characteristics. Observations were at the enrollee-period (pre or post) level. 
Enrollees had either one or two observations depending on whether they were enrolled for 
only one or both of the periods.
Receipt of at least one mammogram over a two-year period was the outcome variable. The 
independent variables were age group (40–49 years vs. 50–59 years), period (2008–2009 vs. 
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2010–2011), an interaction term between age group and period, and controls for the 
relationship of the woman to the policyholder, plan type, region, and comorbidities.
The sample for the difference-in-difference analysis had over five million observations, so 
we used a linear probability model rather than a logit or probit regression to reduce the 
model run time. We used enrollee-level random effects to adjust standard errors for repeated 
observations.
Age-specific analysis—We conducted a separate analysis to assess age-specific changes 
in the proportion of women ages 35–59 years who were screened. We restricted the sample 
to women who met the inclusion criteria in both the pre- and post-period. We compared the 
proportion of women screened by age and assessed the significance of differences in the 
proportion of women screened by age using two-proportion, two-tailed z-tests for 
proportions. Data were analyzed using SAS version 9.3 (SAS Institute Inc, Cary, NC) and 
Stata 12 (StataCorp, College Station, Texas).
Results
We excluded 96,083 women who did not meet the enrollment criteria and 1,922 women who 
had a claim listing a breast cancer diagnosis from the 2008 to 2009 sample. We excluded 
116,960 women who did not meet the enrollment criteria and 2,892 women who had a claim 
listing a breast cancer diagnosis from the 2010 to 2011 sample.
There were 1,947,409 women ages 40–49 years who met the sample inclusion criteria in 
2008–2009, of whom 58.5% received at least one screening mammogram during this period. 
There were 2,451,673 women ages 40–49 years who met the inclusion criteria in 2010–
2011, of whom 56.9% received a screening mammogram. The difference in the proportions 
between 2008–2009 and 2010–2011 was −1.6 percentage points (p < 0.001).
There were 2,064,883 women ages 50–59 years who met the sample inclusion criteria in 
2008–2009, of whom 62.5% received at least one screening mammogram during this period. 
There were 2,607,280 women ages 50–59 years who met the inclusion criteria in 2010–
2011, of whom 62.0% received a screening mammogram. The difference in the proportions 
between 2008–2009 and 2010–2011 was −0.5 percentage points (p <0.001). The unadjusted 
difference-in-difference estimator is −1.1 percentage points (= −1.6 − [−0.5]; p < 0.001).
Table 1 displays the characteristics of the sample. Most differences in patient characteristics 
between time periods within each age group are statistically significant but small. The 
composition of the sample with respect to employee relation (employee vs. dependent) is 
similar across time periods. There has been a small shift away from point-of-service plans to 
plans in the “Other” category, but this may reflect the vagaries of characterizing health plans 
rather than substantive changes in plan design. There was a large decline in the proportion of 
enrollees living in the south and a corresponding increase in the proportion living in the 
northeast and west regions. The proportion of enrollees with selected comorbidities was 
similar across time periods.
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Table 2 displays estimates of the impact of patient characteristics and time period on the 
likelihood of receiving a mammogram over a two-year period. The coefficient on age group 
(ages 40–49 vs. 50–59 years) indicates that the proportion of women ages 40–49 years who 
received a mammogram was 3.1 percentage points lower than the proportion among women 
ages 50–59 years. The coefficient on time period (2010–2011 vs. 2008–2009) indicates that 
there was a secular decline of 0.7 percentage points in the proportion of women screened. 
The coefficient on the interaction of age group and time period indicates that the differential 
change in the proportion of women ages 40–49 years who were screened was −1.2 
percentage points, similar to the unadjusted difference-in-difference estimator of −1.1.
We analyzed the proportion of women screened by age to determine whether declines in the 
proportion of women screened between 2008–2009 and 2010–2011 were larger among 
women near age 40 years. We restricted the sample to women who met the sample inclusion 
criteria in both periods.
Figure 1 shows the proportion of women ages 35–49 years screened between 2008–2009 
and 2010–2011. Women who were 37 years old in 2008 and 2009 were 39 years old in 2010 
and 2011, women who were 38 years old in 2008 and 2009 were 40 years old in 2010 and 
2011, and so forth. The number of women in each one year age group ranged from 90,197 
(women age 40) to 123,493 (women age 51).
In both periods, there is a sharp increase in the proportion of women screened between ages 
37 and 39 years. The proportion of women screened decreased between 2008–2009 and 
2010–2011 for all ages. Differences are significant at the 1% level for each age. Decreases 
are larger among women at the younger end of the age range. For example, among women 
age 37 years, the proportion screened declined by 4.4 percentage points, from 16.9% in 
2008–2009 to 12.5% in 2010–2011. Among women 45 years old, the proportion screened 
declined by 1.3 percentage points, from 58.6% in 2008–2009 to 57.3% in 2010–2011.
In a sensitivity analysis, we examined the proportion of women receiving mammograms by 
age group and time period counting both mammograms billed using screening and 
diagnostic billing codes. The unadjusted difference-in-difference estimator is −0.3 
percentage points (p < 0.001).
Discussion
Consistent with previous studies, we find that the 2009 revision to the USPSTF breast cancer 
screening recommendation led to a small reduction (−1.2 percentage points) in the 
proportion of insured women ages 40–49 years who were screened. Over 50% of women 
age 40 received a screening mammogram in the period 2010–2011, suggesting that the 2009 
revision had little immediate impact on clinical care for insured women. Screening rates 
measured using claims data are generally lower than those measured using surveys where 
respondents self-report receipt of mammograms [25]. If mammograms are not completely 
captured in claims data, then our results would understate screening rates. However, it seems 
more likely that survey data overstate screening rates.
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The relationships between patient characteristics other than age and receipt of mammograms 
were not a focus of the study, but the estimated relationships were in the expected direction 
and had a reasonable magnitude. Women who are primary policyholders are more likely to 
receive a mammogram compared to women who are covered through their spouses, perhaps 
reflecting the unobserved influence of education or personality.
Unlike previous studies, we examined the proportion of women screened for each age in the 
neighborhood of age 40. The size of the effect varied by age, and the pattern of age-specific 
declines suggests that women’s responses to the 2009 revision were subject to inertia: 
Women who were screened previously were probably more likely to continue receiving 
mammograms. We observed the smallest declines among women at the upper end of the 40–
49 years age range, many of whom were probably screened multiple times in the past. We 
observed the largest declines among women at the lower end of the age range, many of 
whom had limited prior experience with screening. However, even among women age 39–41 
years, decreases were small in magnitude.
Our study has a number of limitations. We present screening rates from a population 
comprised mainly of women with group health insurance, and so the results may not be 
generalizable to women who are uninsured, purchase insurance directly, or have Medicare or 
Medicaid. However, the MarketScan insurance claims database captures a sizable share 
(about 25%) of the privately insured population. Many previous studies of the impact of the 
2009 revision to the USPSTF breast cancer screening recommendation relied on survey data 
where receipt of mammography was measured via self-report. Compared to self-reports of 
screening mammograms, insurance claims can measure screening rates more accurately [28, 
29]. The data do not include information about breast cancer risk. Guidelines generally 
apply to average-risk patients, and we may have observed a larger impact of the revision to 
the USPSTF recommendation in a sample that excludes above-average-risk women. 
However, as long as the distribution of risk did not change over time, our estimate of the 
impact will be unbiased.
The ability to accurately distinguish between mammograms performed for screening versus 
diagnosis is unknown [30]. We would not expect the number of diagnostic mammograms to 
change over the relatively short time frame of our study independent of any changes related 
to declines in the use of screening mammography, and our sensitivity analysis including 
diagnostic mammograms also showed a significant reduction in screening.
We used women aged 50–59 years as a control group. The 2009 USPSTF breast cancer 
screening recommendation advised women in this age range to have a mammogram every 
one to two years. The previous version recommended that women receive an annual 
mammogram. The change in the recommended screening frequency may have contributed to 
a decline in the mammography rate among women ages 50–59 years. By not taking this 
change into account, we may have underestimated the impact of the 2009 revision among 
women ages 40–49.
Our study examines only the short-term effect of the revised USPSTF recommendations. 
When changes in guidelines affect practice patterns, the effect is often apparent immediately 
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[31, 32]. The 2009 USPSTF recommendations received a lot of attention in the media, so it 
was not as if physicians were unaware the revisions. However, the recommendations 
addressed a repeated behavior: screening. If patients’ and physicians’ responses are 
influenced by their past actions (i.e., subject to inertia), then it may take some time for the 
impact of changes in practice patterns to become apparent. We find some evidence 
consistent with inertia: Declines in the proportion of women screened were larger among 
women at the younger end of the 40–49 age range, whom we would expect have less prior 
exposure to mammography. However, many women at the younger end of the 40–49 age 
range received mammograms in 2010–2011. A study that analyzes screening among ages 
40–49 in the future may find a larger effect than studies that examined screening behavior 
shortly after the release of the 2009 revision.
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Fig. 1. 
The proportion of women screened by age and period
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Table 1
Characteristics of the sample
Ages 40—49 Ages 50—59
2008–2009 2010–2011 2008–2009 2010–2011
Relation to policyholder
  Employee 1,113,918 (57.2%) 1,387,647 (56.6%) 1,240,995 (60.1%) 1,582,619 (60.7%)
  Spouse/child/other 833,491 (42.8%) 1,064,026 (43.4%) 823,888 (39.9%) 1,027,268 (39.4%)
Plan type
  HMO/PPO/CDHP 1,635,824 (84.0%) 2,059,405 (84.0%) 1,693,204 (82.0%) 2,124,933 (81.5%)
  POS 206,425 (10.6%) 176,520 (7.2%) 233,332 (11.3%) 216,404 (8.3%)
  Other/missing 105,160 (5.4%) 218,199 (8.9%) 138,347 (6.7%) 265,943 (10.2%)
Region
  Northeast 171,372 (8.8%) 394,719 (16.1%) 154,866 (7.5%) 406,736 (15.6%)
  North central 482,957 (24.8%) 593,305 (24.2%) 545,129 (26.4%) 646,605 (24.8%)
  South 962,020 (49.4%) 953,701 (38.9%) 1,007,663 (48.8%) 998,588 (38.3%)
  West 325,217 (16.7%) 505,045 (20.6%) 351,030 (17.0%) 552,743 (21.2%)
  Missing 7,790 (0.4%) 4,903 (0.2%) 8,260 (0.4%) 5,215 (0.2%)
Comorbidities
  Cardiac disease 138,850 (7.1%) 169,901 (6.9%) 228,996 (11.1%) 274,807 (10.5%)
  Hypertension 431,935 (22.2%) 514,361 (21.0%) 788,372 (38.2%) 934,449 (35.8%)
  COPD 199,999 (10.3%) 238,793 (9.7%) 246,547 (11.9%) 294,362 (11.3%)
  Diabetes 145,471 (7.5%) 181,914 (7.4%) 286,399 (13.9%) 347,811 (13.3%)
Cancera 67,965 (3.5%) 85,809 (3.5%) 126,577 (6.1%) 159,566 (6.1%)
  Rheumatoid arthritis 67,965 (3.5%) 90,712 (3.7%) 97,875 (4.7%) 126,714 (4.9%)
  Obesity 103,018 (5.3%) 156,662 (6.4%) 99,321 (4.8%) 151,222 (5.8%)
  Anemia 87,049 (4.5%) 115,474 (4.7%) 75,368 (3.7%) 96,730 (3.7%)
  Alcohol/drug abuse 18,695 (1.0%) 25,743 (1.1%) 16,313 (0.8%) 24,508 (0.9%)
  Depression 253,358 (13.0%) 338,086 (13.8%) 243,450 (11.8%) 325,910 (12.5%)
N 1,947,409 2,451,673 2,064,883 2,607,280
HMO health maintenance organization, PPO preferred provider organization, CDHP consumer-directed health plan, POS point-of-service plan, 
COPD chronic obstructive pulmonary disease
a
Excluding breast cancer
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Table 2
Least squares regression of the impact of the age, period, the interaction between age and period, and other 
enrollee characteristics on the likelihood of receiving a mammogram
Effect 95% CI p value
Ages 40–49 (Ref. 50–59) −0.031 (−0.032, −0.030) <.0001
Year 2010–2011 (Ref: 2008–2009) −0.007 (−0.008, −0.006) <.0001
Interaction: ages 40–49 and year 2010–2011 −0.012 (−0.013, −0.010) <.0001
Relation to policyholder
  Employee 0.033 (0.0324, 0.0336) <.0001
  Spouse/child/other Reference group
Plan type
  HMO/PPO/CDHP −0.008 (−0.009, −0.006) <.0001
  Other/missing −0.023 (−0.025, −0.021) <.0001
  POS Reference group
Region
  Northeast 0.001 (−0.000, 0.0015) 0.3048
  North central 0.031 (0.0294, 0.0318) <.0001
  South −0.017 (−0.018, −0.016) <.0001
  West Reference group
Comorbidity
  Cardiac disease 0.033 (0.0322, 0.0346) <.0001
  Hypertension 0.062 (0.0612, 0.0628) <.0001
  COPD 0.010 (0.0091, 0.0111) <.0001
  Diabetes −0.019 (−0.020, −0.018) <.0001
  Cancera −0.068 (−0.070, −0.066) <.0001
  Rheumatoid arthritis 0.049 (0.0469, 0.0501) <.0001
  Obesity 0.032 (0.0304, 0.0332) <.0001
  Anemia 0.056 (0.0541, 0.0573) <.0001
  Alcohol/drug abuse −0.102 (−0.105, −0.099) <.0001
  Depression 0.045 (0.0436, 0.0456) <.0001
CI confidence interval, HMO health maintenance organization, PPO preferred provider organization, CDHP consumer-directed health plan, POS 
point-of-service plan, COPD chronic obstructive pulmonary disease
a
Excluding breast cancer
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